Description
Non-Fucosylated Anti-Human B7-H4 (Ab-A (Derived from 20502)) is a glycosylation-modified therapeutic biobetter antibody.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced B7-H4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
VTCN1
Full Name
V-set domain containing T cell activation inhibitor 1
Background
This gene encodes a protein belonging to the B7 costimulatory protein family. Proteins in this family are present on the surface of antigen-presenting cells and interact with ligand bound to receptors on the surface of T cells. Studies have shown that high levels of the encoded protein has been correlated with tumor progression. A pseudogene of this gene is located on chromosome 20. Multiple transcript variants encoding different isoforms have been found for this gene.
Alternative Names
VTCN1; V-set domain containing T cell activation inhibitor 1; B7X; B7H4; B7S1; B7-H4; B7h. 5; VCTN1; PRO129
Gene ID
79679
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
Ab-A (Derived from 20502)
Description
Afucosylated B7-H4 antibody (Ab-A) has a 140-fold higher affinity for Fcγ receptor IIIA (V158) than the same antibody (Ab-F) with fucosylated Fc.
Antibody Indication
Cancer
